Di Man, Wang Xiaohong, Wu Jing, Yang Hongya
Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, No. 569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, People's Republic of China.
Arch Gynecol Obstet. 2023 Jun;307(6):1713-1726. doi: 10.1007/s00404-022-06565-6. Epub 2022 Jun 11.
To evaluate the efficacy of manifold ovarian stimulation protocols for patients with poor ovarian response.
PubMed, Embase, Cochrane Library and Web of Science were systematically searched until February 14, 2021. Primary outcomes included clinical pregnancy rate per initiating cycle and low risk of cycle cancellation. Secondary outcomes included number of oocytes retrieved, number of metaphase II (MII) oocytes, number of embryos obtained, number of transferred embryos, endometrial thickness on triggering day and estradiol (E) level on triggering day. The network plot, league table, rank probabilities and forest plot of each outcome measure were drawn. Therapeutic effects were displayed as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs).
This network meta-analysis included 15 trials on 2173 participants with poor ovarian response. Delayed start GnRH antagonist was the best regimen in terms of clinical pregnancy rate per initiating cycle (74.04% probability of being the optimal), low risk of cycle cancellation (75.30%), number of oocytes retrieved (68.67%), number of metaphase II (MII) oocytes (97.98%) and endometrial thickness on triggering day (81.97%), while for E level on triggering day, microdose GnRH agonist (99.25%) was the most preferred. Regarding number of embryos obtained and number of transferred embryos, no statistical significances were found between different ovarian stimulation protocols.
Delayed start GnRH antagonist and microdose GnRH agonist were the two superior regimens in the treatment of poor ovarian response, providing favorable clinical outcomes. Future investigation is needed to confirm and enrich our findings.
评估多种卵巢刺激方案对卵巢反应不良患者的疗效。
系统检索PubMed、Embase、Cochrane图书馆和Web of Science直至2021年2月14日。主要结局包括每个启动周期的临床妊娠率和低周期取消风险。次要结局包括获卵数、中期II(MII)卵母细胞数、获得的胚胎数、移植胚胎数、扳机日的子宫内膜厚度和扳机日的雌二醇(E)水平。绘制了每个结局指标的网状图、排名表、排名概率和森林图。治疗效果以风险比(RRs)或均数差(MDs)及95%置信区间(CIs)表示。
该网状Meta分析纳入了15项针对2173名卵巢反应不良参与者的试验。就每个启动周期的临床妊娠率(成为最佳方案的概率为74.04%)、低周期取消风险(75.30%)、获卵数(68.67%)、中期II(MII)卵母细胞数(97.98%)和扳机日的子宫内膜厚度(81.97%)而言,延迟启动的GnRH拮抗剂是最佳方案,而对于扳机日的E水平,微剂量GnRH激动剂(99.25%)是最优选的。关于获得的胚胎数和移植胚胎数,不同的卵巢刺激方案之间未发现统计学差异。
延迟启动的GnRH拮抗剂和微剂量GnRH激动剂是治疗卵巢反应不良的两种优越方案,可提供良好的临床结局。未来需要进一步研究来证实和丰富我们的发现。